• Quantitative physiology and diagnostic measurements provided the backbone for tracking cardiac function, with cardiac output, blood volume, venous pressure, and flow dynamics guiding disease staging and treatment evaluation in congestive heart failure and hypertension [2], [8], [15], [19].

• MI pathophysiology and coronary disease were explored through arteriosclerosis and thrombosis, collateral circulation development, and circulatory dynamics, forming a unified view of infarct mechanisms and early prognostic indicators [3], [4], [5], [6], [9], [17].

• Electrocardiography and electrophysiology emerged as central investigative tools, enabling detection of infarction and conduction abnormalities through characteristic ECG patterns and conduction-velocity analyses across experimental and clinical studies [5], [7], [12], [14].

• Structural remodeling, including cardiomegaly, fatty infiltration, glycogen-storage–related enlargement, and hypertension-linked remodeling, dominated morphological studies and reframed therapeutic targets for heart failure and vascular disease [10], [11], [13], [18].

• Epidemiology and public-health framing guided recognition of silent myocardial infarction and demographic disease patterns, guiding hospital practice and population-level risk assessment in cardiovascular disease [1], [17], [20].